The Editor in Chief, Dr. Fred Ashbury, members of the editorial board, and our publisher, Springer, wish to thank all of the reviewers who voluntarily commit their expertise and time to give thoughtful, objective feedback to authors to improve the quality of submissions and ultimately papers selected for publication. Below is a list of the people who have contributed as reviewers for 2013. …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.